These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170 [TBL] [Abstract][Full Text] [Related]
9. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same? Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584 [TBL] [Abstract][Full Text] [Related]
10. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Hiddemann W; Martin WR; Sauerland CM; Heinecke A; Büchner T Leukemia; 1990 Mar; 4(3):184-8. PubMed ID: 2314117 [TBL] [Abstract][Full Text] [Related]
11. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075 [TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890 [TBL] [Abstract][Full Text] [Related]
13. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913 [TBL] [Abstract][Full Text] [Related]
14. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126 [TBL] [Abstract][Full Text] [Related]
15. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ; Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062 [TBL] [Abstract][Full Text] [Related]
16. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508 [TBL] [Abstract][Full Text] [Related]
17. Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. Moritake H; Tanaka S; Nakayama H; Miyamura T; Iwamoto S; Shimada A; Terui K; Saito A; Shiba N; Hayashi Y; Tomizawa D; Taga T; Goto H; Hasegawa D; Horibe K; Mizutani S; Adachi S Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28233452 [No Abstract] [Full Text] [Related]
19. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide. Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733 [TBL] [Abstract][Full Text] [Related]
20. Current and emerging therapies for acute myeloid leukemia. Robak T; Wierzbowska A Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]